Innoviva Inc.
951 Gateway Boulevard
South San Francisco
California
94080
United States
Tel: 650-808-6000
Website: http://www.thrxinc.com/
452 articles about Innoviva Inc.
-
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
3/4/2024
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company") today announced that it has entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's largest shareholder.
-
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
2/29/2024
Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2023 and highlighted select corporate achievements.
-
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
11/1/2023
Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the third quarter ended September 30, 2023, highlighted select corporate achievements and provided an overview of its key business initiatives.
-
Innoviva to Participate in the Cantor Global Healthcare Conference
9/19/2023
Innoviva, Inc. today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Cantor Global Healthcare Conference in New York, NY on Wednesday, September 27, 2023 at 1:50 p.m. Eastern Time.
-
Innoviva Appoints Stephen Basso as Chief Financial Officer
8/25/2023
Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced the appointment of Stephen Basso as its Chief Financial Officer, effective August 21, 2023.
-
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
8/2/2023
Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the second quarter ended June 30, 2023, highlighted select corporate achievements and provided an overview of its key business initiatives.
-
The regulator approved Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia. The NDA was filed by Entasis Therapeutics, which Innoviva acquired in 2022.
-
Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
5/9/2023
Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or “the Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the first quarter ended March 31, 2023, highlighted select corporate achievements and provided an overview of its key business initiatives.
-
Innoviva Announces Retirement of Board Chairman
4/28/2023
Innoviva, Inc. and George Bickerstaff, III, Chairman of the Board of Directors of the Company announced that Mr. Bickerstaff would not stand for reelection at the Company’s 2023 Annual Meeting.
-
A unanimous FDA committee vote supported the favorable risk-benefit profile of Innoviva’s sulbactam-durlobactam for hospital-acquired A. baumannii infections.
-
Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee
4/17/2023
Innoviva, Inc. today announced that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) unanimously voted 12-0 in support of approval based on a favorable benefit-risk assessment of sulbactam-durlobactam for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter).
-
Innoviva Stock Trading Halted Today
4/17/2023
Innoviva, Inc., a diversified holding company with a portfolio of royalties and other healthcare assets, announced that Nasdaq has halted trading of Innoviva’s common stock.
-
Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic
3/13/2023
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee will convene April 17, 2023 to review data supporting the new drug application (NDA) for sulbactam-durlobactam (SUL-DUR).
-
Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress
2/28/2023
Innoviva, Inc. today reported financial results for the fourth quarter ended December 31, 2022.
-
Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)
11/30/2022
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the new drug application (NDA) for SUL-DUR, an investigational drug for the treatment of infections caused by Acinetobacter baumannii-calcoaceticus complex (ABC), including multi-drug resistant and carbapenem-resistant strains.
-
Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
11/9/2022
Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the third quarter ended September 30, 2022.
-
La Jolla Pharmaceutical, a Wholly Owned Subsidiary of Innoviva, Inc., Announces Data on XERAVA (eravacycline) to be Presented at IDWeek 2022
10/14/2022
La Jolla Pharmaceutical Company today announced that five abstracts highlighting XERAVA (eravacycline) have been selected for poster presentation at IDWeek 2022, the annual meeting of the Infectious Disease Society of America taking place October 19-23, 2022 in Washington, D.C.
-
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022Six abstracts selected for presentation, including three oral presentations
10/12/2022
Entasis Therapeutics Holdings Inc. announced that six abstracts highlighting sulbactam-durlobactam have been selected for presentation at IDWeek 2022, the annual meeting of the Infectious Disease Society of America taking place October 19-23, 2022 in Washington, D.C.
-
Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
9/8/2022
Innoviva, Inc. announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14th at 11:10 a.m. Eastern Time.
-
Innoviva Completes Acquisition of La Jolla Pharmaceutical
8/22/2022
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of La Jolla Pharmaceutical Company (Nasdaq: LJPC) (“La Jolla”) at a price of $6.23 per share (the “Offer Price”).